MedTrace Logo

Probiotics as Adjuvant Treatment for Bacterial Vaginosis

NCT03894813 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2021-07-09

Study results available
· View outcomes & findings →

Summary

The investigators are trying to determine if oral probiotics (Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) (30 days)with metronidazole vaginal suppositories(7 days) is better than using metronidazole vaginal suppositories only in preventing the recurrence of bacterial vaginosis (BV).

Conditions

  • Bacterial Vaginosis

Interventions

DRUG

"Probiotics" and "Metronidazole"

Oral probiotics (Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) (qd, 30 days)+Metronidazole Suppositories (qd, 7 days)

DRUG

Metronidazole Vaginal

Metronidazole Suppositories,qd, 7 days

Sponsors & Collaborators

  • BGI, China

    collaborator OTHER

  • Peking University Shenzhen Hospital

    lead OTHER

Principal Investigators

  • Ruifang Wu, M.D. · Dept of Obstetrics and Gynecology,Peking University Shenzhen Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-26
Primary Completion
2020-12-30
Completion
2020-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03894813 on ClinicalTrials.gov